Condition

Fibrosis clinical trials and research

• 14Clinical trials
• 719NIH research projects
• 1New in 30 days
• 9Countries

Newest Fibrosis clinical trials

All recruiting trials (14)

• Imaging endometriosis with a special PET tracer in adult women

  This study tests whether a PET/CT scan using [18F]AlF-FAPI-74 can help detect endometriosis lesions in women who are planning laparoscopy.

  Recruiting Universitaire Ziekenhuizen KU Leuven · Leuven · NCT07876648

• Inhaled mosliciguat for pulmonary hypertension in interstitial lung disease (PH-ILD) patients

  This study tests inhaled mosliciguat versus placebo in people with PH-ILD to see if it helps with their condition.

  Recruiting at 3 sites Phase 3 Pulmovant, Inc. · Kissimmee, Florida and 2 other locations · NCT07816185

• Copper supplementation for people with cirrhosis

  This trial will try giving copper supplements to adults with cirrhosis who have low copper levels or signs of copper deficiency to see if liver-related health improves.

  Recruiting University of Washington · Seattle, Washington · NCT07471542

• Western Sweden Systemic Sclerosis Project

  This project will collect blood, skin and DNA samples from people with systemic sclerosis in Western Sweden to try to find genes, proteins, and immune changes linked to how the disease starts and gets worse.

  Recruiting Sahlgrenska University Hospital · Gothenburg, Sweden · NCT07345052

• Mosliciguat added to inhaled treprostinil for pulmonary hypertension from ILD

  This trial tests whether adding inhaled mosliciguat to your inhaled treprostinil is safe and tolerable for people with pulmonary hypertension caused by interstitial lung disease.

  Recruiting at 13 sites Phase 2 Pulmovant, Inc. · Santa Barbara, California and 12 other locations · NCT07333183

• Reversing radiotherapy-related fibrosis and lymphedema in head and neck cancer survivors

  This trial will test whether adding one of several drugs (pravastatin, pentoxifylline, ketoprofen, or pirfenidone) to standard care can prevent or reduce radiation-related fibrosis and lymphedema in people treated for head and neck cancer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06912763

• Using a Gastric Bypass Stent to Treat Liver Fibrosis in Obese Patients

  This study is testing a new stent treatment for liver fibrosis in obese patients to see if it helps improve their liver health and aids in weight loss.

  Recruiting at 2 sites Mdcecro LLC · Riga, Riga and 1 other locations · NCT06561529

• Prophylactic pravastatin versus pentoxifylline plus vitamin E to prevent radiation-related lymphedema and fibrosis

  This trial will test whether taking pravastatin or taking pentoxifylline with vitamin E can reduce radiation-related lymphedema and fibrosis in adults receiving radiotherapy for oropharyngeal cancer.

  Recruiting Phase 2 M.D. Anderson Cancer Center · Houston, Texas · NCT06494111

• Assessing diaphragm function in patients with respiratory diseases

  This study is testing how well the diaphragm works in people with respiratory diseases to see if it affects their breathing difficulties and overall health.

  Recruiting RWTH Aachen University · Aachen, North Rhine-Westphalia · NCT05903001

• Evaluating spa therapy for skin fibrosis after breast cancer radiotherapy

  This study is testing if spa therapy can help improve skin problems and quality of life for breast cancer survivors who have had radiation treatment.

  Recruiting at 12 sites Association Francaise pour la Recherche Thermale · Bordeaux and 12 other locations · NCT05874492

• Assessing liver fat levels in HIV/AIDS patients on different medications

  This study is trying to see how different HIV medications affect liver fat levels in patients living with HIV/AIDS to understand the risk of liver disease.

  Recruiting Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT05330923

• Evaluating the progression of pancreatitis from acute to chronic stages

  This study is trying to see how acute pancreatitis can turn into chronic pancreatitis over time by following patients with different stages of the condition and using advanced imaging and tests.

  Recruiting at 3 sites Copenhagen University Hospital, Hvidovre · Hvidovre, Capital Region Denmark and 2 other locations · NCT03853447

• Screening for liver fibrosis in at-risk populations using non-invasive methods

  This study is testing non-invasive methods to check for advanced liver damage in people at risk, like those with a history of heavy drinking or metabolic syndrome, to see how well these methods work compared to traditional tests.

  Recruiting Odense University Hospital · Odense · NCT03308916

• Biorepository for liver disease samples

  This study is collecting samples from patients with liver diseases to help researchers find better treatments and improve care for these conditions.

  Recruiting State University of New York at Buffalo · Buffalo, New York · NCT03025074

NIH-funded research (newest 40 of 719)

Early-stage science funded by the US National Institutes of Health. Most of these projects don't enroll patients, but they show what is being worked on.

• Interface between immune cells and scarring in the eye

  This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.

  NIH research University of Missouri-Columbia · Columbia, United States · NIH-11609392

• How often to treat schistosomiasis to protect the liver

  A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.

  NIH research Rhode Island Hospital · Providence, United States · NIH-11607872

• Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring

  A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.

  NIH research University of Texas Hlth Sci Ctr Houston · Houston, United States · NIH-11603221

• Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa

  This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.

  NIH research University of Washington · Seattle, United States · NIH-11594185

• Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa

  This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.

  NIH research University of Washington · Seattle, United States · NIH-11594184

• Molecular clues to progressive lung scarring

  Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11577962

• Alveolar Cell Dysfunction in Pulmonary Fibrosis: Using SFTPC Mutations to Find New Targets

  This grant explores how rare SFTPC mutations in alveolar cells may drive IPF and seeks new molecular targets to improve treatment.

  NIH research University of Pennsylvania · Philadelphia, United States · NIH-11575419

• Blocking CFTR in the cervix to prevent conception without hormones

  A non-hormonal approach aims to stop sperm from entering the uterus by making cervical mucus too thick for sperm, potentially offering a new contraception option.

  NIH research Oregon Health & Science University · Portland, United States · NIH-11565149

• Iron and scar-forming cells in the lungs (IPF)

  Researchers are exploring how iron in the lungs may drive the scarring seen in idiopathic pulmonary fibrosis and whether this could lead to new therapies.

  NIH research Oklahoma State University Stillwater · Stillwater, United States · NIH-11559120

• Inflammation and scarring in pulmonary TB: the INFIN-TB study

  A study of people with newly diagnosed drug-susceptible TB, with and without HIV, to understand why some patients develop long-term lung problems after TB and how to prevent them.

  NIH research Emory University · Atlanta, United States · NIH-11551510

• Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis

  A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).

  NIH research Oleolive, INC. · Shreveport, United States · NIH-11550918

• Understanding how DVT forms and heals to prevent vein scarring

  This NIH grant supports a physician-scientist to study why deep vein clots form and how vein walls get scarred, with the goal of improving long-term outcomes for patients who develop DVT.

  NIH research Portland VA Medical Center · Portland, United States · NIH-11522579

• Fibro-adipogenic progenitors and scar tissue in skeletal muscle fibrosis

  A study at UC Davis explores how scar-forming cells and the muscle’s surroundings affect fibrosis and how this could impact future therapies for Duchenne muscular dystrophy and other muscle diseases.

  NIH research University of California at Davis · Davis, United States · NIH-11520826

• Protein-based MRI contrast agent to image lung fibrosis in kids and adults

  A new protein MRI contrast agent is being developed to help doctors noninvasively detect and measure lung fibrosis, including in children and other patients, using safer MRI imaging.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11520223

• Point-of-care test to spot risk of liver scarring from Schistosoma japonicum

  This project aims to develop a simple clinic test to find people with S. japonicum infection who are likely to develop worsening liver scarring so they can get treatment earlier.

  NIH research Rhode Island Hospital · Providence, United States · NIH-11509730

• Role of SMAD1/5/8 signaling in liver fibrosis

  This grant explores how specific liver cell signals influence scarring (fibrosis) in the liver, with a focus on people who have alcohol-related liver disease or related conditions.

  NIH research University of Arizona · Tucson, United States · NIH-11504353

• Screening new compounds to reverse gene signatures in IPF lungs

  A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).

  NIH research Henry Ford Health + Michigan State University Health Sciences · East Lansing, United States · NIH-11494256

• Role of lactate transporters in lung scarring

  Aims to see if blocking lactate transporters can slow or stop scar-forming cells from thickening the lungs in people with fibrotic lung disease.

  NIH research Rhode Island Hospital · Providence, United States · NIH-11477025

• Targeting TGF-βRII to treat alcoholic liver fibrosis

  A study to test a new peptide that blocks a key fibrosis signal and a gene-silencing approach to help reverse liver fibrosis caused by alcohol use.

  NIH research University of Missouri Kansas City · Kansas City, United States · NIH-11466092

• Optimizing Treatments for People with Cystic Fibrosis on Highly Effective Modulator Therapy

  A real-world study in people with cystic fibrosis on highly effective CFTR modulator therapy to understand how traditional CF treatments can be adjusted safely.

  NIH research Rutgers Biomedical and Health Sciences · Newark, UNITED STATES · NIH-11465858

• Understanding how a specific type of immune cell drives lung scarring and how to target it

  A research grant aims to learn exactly how a type of lung macrophage contributes to pulmonary fibrosis and whether targeting a receptor called TREM2 could slow or stop disease progression in people with IPF.

  NIH research University of Alabama at Birmingham · Birmingham, United States · NIH-11465744

• Targeted Shroom3-Rock interaction to reduce kidney scarring in CKD

  Aims to block a specific protein interaction in people with chronic kidney disease to prevent scarring and loss of kidney function.

  NIH research Yale University · New Haven, United States · NIH-11459312

• Formyl peptide receptor links inflammation to lung disease in rheumatoid arthritis

  This grant looks at how a receptor on immune cells may drive lung inflammation in people with rheumatoid arthritis and related conditions.

  NIH research University of Washington · Seattle, United States · NIH-11451453

• Understanding how RNA binding proteins drive liver scarring and how to slow it down

  A researcher team is studying how certain RNA binding proteins, especially LARP6, regulate the liver’s scar-building process in alcoholic liver disease to identify potential ways to reduce fibrosis.

  NIH research Sanford Burnham Prebys Medical Discovery Institute · La Jolla, United States · NIH-11449893

• Alternative polyadenylation in heart fibrosis

  Researchers are testing how changes in gene regulation after a gene is read (via APA) influence heart fibrosis and whether adjusting this process could help heart failure.

  NIH research Methodist Hospital Research Institute · Houston, United States · NIH-11449446

• p53 acetylation and alveolar stem cell aging in progressive lung fibrosis

  Scientists are studying how changes to a cancer-related protein, p53, affect aging lung cells and contribute to a scary lung disease called IPF.

  NIH research Cedars-Sinai Medical Center · Los Angeles, United States · NIH-11449164

• Determinants of Early Lung Fibrosis Progression

  Researchers are studying why early lung scarring happens and which biomarkers predict it, aiming to help people at risk catch and prevent progression.

  NIH research University of Colorado Denver · Aurora, UNITED STATES · NIH-11448297

• Targeted nanoparticle therapy for lung fibrosis

  A researcher team is testing inhaled nanoparticles that deliver medicine directly to the lungs to slow or stop scarring in people with pulmonary fibrosis.

  NIH research Texas Engineering Experiment Station · College Station, United States · NIH-11448075

• Elastin-like particles to deliver gene therapies for cystic fibrosis

  A new nanoparticle system is being developed to deliver genetic therapies directly to the lungs of people with cystic fibrosis, including those with nonsense mutations.

  NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11447142

• How SOCS1 and PIAS1 control fibrotic skin signals (for people with scleroderma)

  This grant seeks to understand how specific proteins control scarring in the skin of people with scleroderma, with the goal of guiding safer therapies.

  NIH research Yale University · New Haven, United States · NIH-11446838

• Non-invasive kidney injury detection using blood and urine markers

  Researchers are developing a non-invasive way to gauge kidney damage, based on simple blood and urine tests, using data from patients who need kidney biopsies.

  NIH research Johns Hopkins University · Baltimore, United States · NIH-11446560

• Blocking NOX4 to reduce muscle scarring after spinal cord injury

  A drug that blocks the NOX4 enzyme to lower muscle scarring and help people with spinal cord injuries regain muscle strength.

  NIH research Veterans Health Administration · Gainesville, United States · NIH-11446449

• Pharmacogenomic Predictors of Clinical Responses in Cystic Fibrosis using Targeted WGS

  A study looking at how genetic information from whole-genome sequencing can predict how people with cystic fibrosis respond to medications, using a focused set of pharmacogenomic genes.

  NIH research Univ of North Carolina Chapel Hill · Chapel Hill, United States · NIH-11445429

• Imaging scar tissue formation after nerve injuries

  A small NIH grant aims to visually track scar tissue forming around injured nerves in animal models to help surgeons plan and improve outcomes.

  NIH research Washington University · Saint Louis, United States · NIH-11445204

• Understanding how TLR4 in mesenchymal cells affects muscle decline after cancer radiation in kids

  This grant looks at why radiation therapy used for pediatric cancers may cause long-term muscle weakness and scarring, focusing on a specific immune pathway in tissue-supporting cells.

  NIH research Duke University · Durham, United States · NIH-11445111

• Understanding how tobacco smoke changes lung fibroblasts in pulmonary fibrosis

  A study exploring how cigarette smoke affects lung cells to drive fibrosis, with a focus on a protein called PRMT5 and potential ways to slow disease progression.

  NIH research University of California at Davis · Davis, United States · NIH-11443942

• Blocking a kidney fibrotic pathway to protect kidneys in AKI

  A small, patient-friendly study looks at whether stopping a specific protein interaction can reduce kidney scarring after injury.

  NIH research Boston Children's Hospital · Boston, United States · NIH-11441447

• Ceftaroline-meropenem combo to beat MRSA in cystic fibrosis

  A new combination antibiotic approach is being tested to help people with cystic fibrosis who have MRSA infections that resist standard treatments.

  NIH research Mainehealth · Portland, United States · NIH-11439521

• Primary Cilia and cAMP: Helping Fibrosis Patients Heal

  A small NIH-funded project will study how a cellular signaling molecule called cAMP helps skin and organ fibroblasts stop causing scarring, with the goal of guiding future therapies for fibrosis.

  NIH research University of Michigan at Ann Arbor · Ann Arbor, United States · NIH-11438767

• MMP7-Positive Liver Cells Driving Fibrosis in Biliary Atresia

  This study explores a specific liver cell type marked by MMP7 to understand why scarring progresses in biliary atresia and how it might be slowed.

  NIH research Icahn School of Medicine at Mount Sinai · New York, United States · NIH-11438027

Related topics

Quick answers

How many Fibrosis clinical trials are recruiting right now?

14, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 9 countries. The most sites are in United States (6 trials), Denmark (2 trials), China (1 trial), Sweden (1 trial), Belgium (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 3, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →